{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,13]],"date-time":"2026-10-13T19:34:15Z","timestamp":1791920055926,"version":"4.3.4"},"reference-count":18,"publisher":"Wiley","issue":"2","license":[{"start":{"date-parts":[[2015,9,1]],"date-time":"2015-09-01T00:00:00Z","timestamp":1441065600000},"content-version":"tdm","delay-in-days":629,"URL":"http:\/\/doi.wiley.com\/10.1002\/tdm_license_1.1"}],"content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":["The Journal of Clinical Pharmacology"],"published-print":{"date-parts":[[2014,2]]},"DOI":"10.1002\/jcph.239","type":"journal-article","created":{"date-parts":[[2013,11,25]],"date-time":"2013-11-25T10:31:05Z","timestamp":1385375465000},"page":"168-178","source":"Crossref","is-referenced-by-count":170,"title":["Multiple doses of sclerostin antibody romosozumab in healthy men and postmenopausal women with low bone mass: A randomized, double-blind, placebo-controlled study"],"prefix":"10.1002","volume":"54","author":[{"given":"Desmond","family":"Padhi","sequence":"first","affiliation":[{"name":"Amgen Inc.; Thousand Oaks CA USA"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Mark","family":"Allison","sequence":"additional","affiliation":[{"name":"MDS Pharma Services (US), Inc.; Tempe AZ USA"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Alan J.","family":"Kivitz","sequence":"additional","affiliation":[{"name":"Altoona Center for Clinical Research; Duncansville PA USA"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Maria J.","family":"Gutierrez","sequence":"additional","affiliation":[{"name":"Comprehensive Phase One; Miramar FL USA"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Brian","family":"Stouch","sequence":"additional","affiliation":[{"name":"Amgen Inc.; Thousand Oaks CA USA"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Christine","family":"Wang","sequence":"additional","affiliation":[{"name":"Amgen Inc.; Thousand Oaks CA USA"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Graham","family":"Jang","sequence":"additional","affiliation":[{"name":"Amgen Inc.; Thousand Oaks CA USA"}],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"311","published-online":{"date-parts":[[2013,12,11]]},"reference":[{"key":"10.1002\/jcph.239-BIB0001|jcph239-cit-0001","unstructured":"http:\/\/www.nof.org\/advocacy\/resources\/prevalencereport 2012"},{"issue":"9","key":"10.1002\/jcph.239-BIB0002|jcph239-cit-0002","doi-asserted-by":"crossref","first-page":"1897","DOI":"10.1002\/jbmr.161","article-title":"Sclerostin: a gem from the genome leads to bone-building antibodies","volume":"25","author":"Paszty","year":"2010","journal-title":"J Bone Miner Res."},{"issue":"3","key":"10.1002\/jcph.239-BIB0003|jcph239-cit-0003","doi-asserted-by":"crossref","first-page":"577","DOI":"10.1086\/318811","article-title":"Bone dysplasia sclerosteosis results from loss of the SOST gene product, a novel cystine knot-containing protein","volume":"68","author":"Brunkow","year":"2001","journal-title":"Am J Hum Genet."},{"issue":"5","key":"10.1002\/jcph.239-BIB0004|jcph239-cit-0004","doi-asserted-by":"crossref","first-page":"537","DOI":"10.1093\/hmg\/10.5.537","article-title":"Increased bone density in sclerosteosis is due to the deficiency of a novel secreted protein (SOST)","volume":"10","author":"Balemans","year":"2001","journal-title":"Hum Mol Genet."},{"issue":"6","key":"10.1002\/jcph.239-BIB0005|jcph239-cit-0005","doi-asserted-by":"crossref","first-page":"860","DOI":"10.1359\/jbmr.080216","article-title":"Targeted deletion of the sclerostin gene in mice results in increased bone formation and bone strength","volume":"23","author":"Li","year":"2008","journal-title":"J Bone Miner Res."},{"issue":"4","key":"10.1002\/jcph.239-BIB0006|jcph239-cit-0006","doi-asserted-by":"crossref","first-page":"578","DOI":"10.1359\/jbmr.081206","article-title":"Sclerostin antibody treatment increases bone formation, bone mass, and bone strength in a rat model of postmenopausal osteoporosis","volume":"24","author":"Li","year":"2009","journal-title":"J Bone Miner Res."},{"issue":"5","key":"10.1002\/jcph.239-BIB0007|jcph239-cit-0007","doi-asserted-by":"crossref","first-page":"948","DOI":"10.1002\/jbmr.14","article-title":"Two doses of sclerostin antibody in cynomolgus monkeys increases bone formation, bone mineral density, and bone strength","volume":"25","author":"Ominsky","year":"2010","journal-title":"J Bone Miner Res."},{"issue":"6","key":"10.1002\/jcph.239-BIB0008|jcph239-cit-0008","doi-asserted-by":"crossref","first-page":"2635","DOI":"10.1210\/en.2007-0270","article-title":"Targeting the Wnt\/beta-catenin pathway to regulate bone formation in the adult skeleton","volume":"148","author":"Baron","year":"2007","journal-title":"Endocrinology."},{"issue":"20","key":"10.1002\/jcph.239-BIB0009|jcph239-cit-0009","doi-asserted-by":"crossref","first-page":"19883","DOI":"10.1074\/jbc.M413274200","article-title":"Sclerostin binds to LRP5\/6 and antagonizes canonical Wnt signaling","volume":"280","author":"Li","year":"2005","journal-title":"J Biol Chem."},{"issue":"11","key":"10.1002\/jcph.239-BIB0010|jcph239-cit-0010","doi-asserted-by":"crossref","first-page":"1738","DOI":"10.1359\/jbmr.060810","article-title":"Bone density ligand, Sclerostin, directly interacts with LRP5 but not LRP5G171V to modulate Wnt activity","volume":"21","author":"Ellies","year":"2006","journal-title":"J Bone Miner Res."},{"issue":"1","key":"10.1002\/jcph.239-BIB0011|jcph239-cit-0011","doi-asserted-by":"crossref","first-page":"19","DOI":"10.1002\/jbmr.173","article-title":"Single-dose, placebo-controlled, randomized study of AMG 785, a sclerostin monoclonal antibody","volume":"26","author":"Padhi","year":"2011","journal-title":"J Bone Miner Res."},{"issue":"8","key":"10.1002\/jcph.239-BIB0012|jcph239-cit-0012","doi-asserted-by":"crossref","first-page":"851","DOI":"10.1097\/gme.0b013e31820b80f1","article-title":"Effect of zoledronic acid compared with raloxifene on bone turnover markers in postmenopausal women with low bone density","volume":"18","author":"Bachmann","year":"2011","journal-title":"Menopause."},{"issue":"7","key":"10.1002\/jcph.239-BIB0013|jcph239-cit-0013","doi-asserted-by":"crossref","first-page":"2463","DOI":"10.1210\/jc.2008-0926","article-title":"A revised clinician's guide to the prevention and treatment of osteoporosis","volume":"93","author":"Dawson-Hughes","year":"2008","journal-title":"J Clin Endocrinol Metab."},{"issue":"1","key":"10.1002\/jcph.239-BIB0014|jcph239-cit-0014","doi-asserted-by":"crossref","first-page":"25","DOI":"10.1097\/gme.0b013e3181c617e6","article-title":"Management of osteoporosis in postmenopausal women: 2010 position statement of The North American Menopause Society","volume":"17","year":"2010","journal-title":"Menopause."},{"key":"10.1002\/jcph.239-BIB0015|jcph239-cit-0015","doi-asserted-by":"crossref","first-page":"1","DOI":"10.4158\/EP.16.S3.1","article-title":"American association of clinical endocrinologists medical guidelines for clinical practice for the diagnosis and treatment of postmenopausal osteoporosis","volume":"16","author":"Watts","year":"2010","journal-title":"Endocr Pract."},{"issue":"1","key":"10.1002\/jcph.239-BIB0016|jcph239-cit-0016","doi-asserted-by":"crossref","first-page":"219","DOI":"10.1007\/s00198-012-2159-7","article-title":"Effects of a single injection of teriparatide on bone turnover markers in postmenopausal women","volume":"24","author":"Shiraki","year":"2013","journal-title":"Osteoporos Int."},{"key":"10.1002\/jcph.239-BIB0017|jcph239-cit-0017","volume-title":"FORTEO\u2122 (teriparatide [rDNA origin] injection) prescribing information","year":"2012"},{"issue":"15","key":"10.1002\/jcph.239-BIB0018|jcph239-cit-0018","doi-asserted-by":"crossref","first-page":"1762","DOI":"10.1001\/archinte.165.15.1762","article-title":"Opposite bone remodeling effects of teriparatide and alendronate in increasing bone mass","volume":"165","author":"McClung","year":"2005","journal-title":"Arch Intern Med."}],"container-title":["The Journal of Clinical Pharmacology"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.wiley.com\/onlinelibrary\/tdm\/v1\/articles\/10.1002%2Fjcph.239","content-type":"unspecified","content-version":"vor","intended-application":"text-mining"},{"URL":"http:\/\/onlinelibrary.wiley.com\/wol1\/doi\/10.1002\/jcph.239\/fullpdf","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2022,7,14]],"date-time":"2022-07-14T13:03:04Z","timestamp":1657803784000},"score":1,"resource":{"primary":{"URL":"https:\/\/onlinelibrary.wiley.com\/doi\/10.1002\/jcph.239"}},"subtitle":["The Journal of Clinical Pharmacology"],"short-title":[],"issued":{"date-parts":[[2013,12,11]]},"references-count":18,"journal-issue":{"issue":"2","published-print":{"date-parts":[[2014,2]]}},"URL":"https:\/\/doi.org\/10.1002\/jcph.239","relation":{},"ISSN":["0091-2700"],"issn-type":[{"value":"0091-2700","type":"print"}],"subject":[],"published":{"date-parts":[[2013,12,11]]}}}